Knight Therapeutics Inc.
TSX:GUD.TO · Toronto Stock Exchange
+$0.07 today
Vol 0.04M · Avg 0.10M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-0.7%
avg 1.1%
ROIC
-0.2%
avg -0.3%
ROA
-0.5%
avg 1.1%
Analysis
ROIC is currently the strongest return metric at -0.2% versus its period average of -0.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Samira Sakhia | President, Chief Executive Officer & Director | $1.44M | — | 58 | — | — |
Arvind Utchanah | Chief Financial Officer | $1.12M | — | — | — | — |
Amal Khouri | Chief Business Officer | $1.06M | — | — | — | — |
Christine Poulin | General Manager of Canada | $789,221.00 | — | — | — | — |
Jonathan Ross Goodman | Executive Chairman | $528,444.00 | — | 57 | — | — |
Susan Caroline Emblem | Global Vice President of Human Resources | $482,414.00 | — | — | — | — |
Monica Percario | Global Vice President of Regulatory & Quality | $480,574.00 | — | — | — | — |
Henrique Dias | Global Vice President of Marketing | $479,789.00 | — | — | — | — |
Leopoldo Bosano | Vice-President of Manufacturing & Operations | $478,923.00 | — | — | — | — |
Melanie Groleau | Global Vice President of Medical & Clinical | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -21.4% | +6.2% (12yr)1 analysts |
| Revenue | N/A | N/A | +129.3% | +38.1% (12yr)1 analysts |
| Net Income | N/A | N/A | -11.0% | +3.1% (12yr)1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +129.3% over three years. Forward estimates point to Revenue at +38.1% (12yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Bright Minds Biosciences Inc.
DRUG.CN
$650.96M
Kneat.com, Inc.
TSX:KSI.TO
$618.13M
Verano Holdings Corp.
VRNO.NE
$594.30M
Vitalhub Corp.
TSX:VHI.TO
$453.89M
Cipher Pharmaceuticals Inc.
TSX:CPH.TO
$408.04M
Cresco Labs Inc.
CL.CN
$407.36M
TerrAscend Corp.
TSX:TSND.TO
$284.80M
Canopy Growth Corporation
TSX:WEED.TO
$244.44M
Aurora Cannabis Inc.
TSX:ACB.TO
$234.78M
OrganiGram Holdings Inc.
TSX:OGI.TO
$189.01M
Who manages GUD.TO?
Knight Therapeutics Inc. (GUD.TO) lists 10 active executives. The top listed executive is Arvind Utchanah, Chief Financial Officer.
Explore More
Continue the stock analysis
Jump to another research area for this company.